Mecasermin

Drug Profile

Mecasermin

Alternative Names: FK 780; IGF-1; Increlex; Insulin-like growth factor-1; rhIGF-I; Somatomedin-1

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genentech
  • Developer Ipsen; Ipsen Biopharmaceuticals; Tercica
  • Class Antihyperglycaemics; Growth factors; Peptides
  • Mechanism of Action Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short stature
  • New Molecular Entity No

Highest Development Phases

  • Marketed Short stature
  • Discontinued Diabetes mellitus

Most Recent Events

  • 16 Feb 2016 Biomarkers information updated
  • 09 May 2014 9162573 - sale figures for North America - haven't added
  • 26 Feb 2013 Tercica is now called Ipsen Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top